Metformin for weight control in pediatric patients on atypical antipsychotic medication

Journal of Child and Adolescent Psychopharmacology

Volumn 19, Issue 3, 2009, Pages 275-279

  Shin, Lauren ^a,b,d,e   Bregman, Hallie ^a,b,d   Breeze, Janis L ^a,b,c,d   Noyes, Nancy ^a,b   Frazier, Jean A ^a,b,c,d  

^a Child Psychiatry Department   (United States)

^b CAMBRIDGE HEALTH ALLIANCE   (United States)

^c MCLEAN HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e CAMBRIDGE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; GLUCOSE; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; RISPERIDONE; TRIACYLGLYCEROL;

ADOLESCENT; ADULT; ANXIETY DISORDER; ARTICLE; ATTENTION; AUTISM; BIPOLAR DISORDER; BODY MASS; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DECREASED APPETITE; DROWSINESS; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; IRRITABILITY; LIPID BLOOD LEVEL; MALE; MUSCULOSKELETAL PAIN; OUTCOME ASSESSMENT; SCHIZOPHRENIA; SCHOOL CHILD; SIDE EFFECT; TASTE DISORDER; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; WEIGHT CONTROL; WEIGHT GAIN;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; BLOOD GLUCOSE; BODY MASS INDEX; CHILD; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; MENTAL DISORDERS; METFORMIN; TRIGLYCERIDES; WAIST CIRCUMFERENCE; WEIGHT GAIN; WEIGHT LOSS;

EID: 67650895042     PISSN: 10445463     EISSN: None     Source Type: Journal    
DOI: 10.1089/cap.2008.094     Document Type: Article

References (18)

1. Baptista T, Martinez J, Lacruz A, Rangel N, Beaulieu S, Serrano A, Arape Y, Martinez M, de Mendoza S, Teneud L, Hernandez L: Metformin for prevention of weight gain and insulin resistance with olanzapine: A double-blind placebo-controlledtrial. Can J Psychiatry 51:192-196, 2006.
2. Bridger T, MacDonald S, Baltzer F, Rodd C: Randomized placebo-controlled trial of metformin for adolescents with polycystic ovary syndrome. Arch Pediatr Adolesc Med 160:241-246, 2006.
3. Findling RL, Steiner H, Weller EB: Use of antipsychotics inchildren and adolescents. J Clin Psychiatry 66:S29-S40, 2005.
4. Freemark M, Bursey D: The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes.Pediatrics 107:E55, 2001.
5. Glueck CJ, Aregawi D, Winiarska M, Agloria M, Luo G, Sieve L, Wang P: Metformin-diet ameliorates coronary heart disease risk factors and facilitates resumption of regular menses in adolescents with polycystic ovary syndrome. J Pediatr EndocrinolMetab 19:831-842, 2006.
6. Jin H, Meyer JM, Jeste DV: Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: An analysis of 45 publishedcases. Ann Clin Psychiatry 14:59-64, 2002.
7. Jones KL, Arslanian S, Peterokova VA, Park JS, Tomlinson MJ: Effect of metformin in pediatric patients with type 2 diabetes: Arandomized controlled trial. Diabetes Care 25:89-94, 2002.
8. Kay JP, Alemzadeh R, Langley G, D'Angelo L, Smith P, Holshouser S: Beneficial effects of metformin in normoglycemicmorbidly obese adolescents. Metabolism 50:1457-1461, 2001.
9. Kenward MG, Roger JH: Small sample inference for fixed effectsfrom restricted maximum likelihood. Biometrics 53:983-997, 1997.
10. Klein DJ, Cottingham EM, Sorter M, Barton BA, Morrison JA: A randomized, double-blind, placebo-controlled trial of metformin treatment of weight gain associated with initiation of atypical antipsychotic therapy in children and adolescents.Am J Psychiatry 163:2072-209, 2006.
11. Morrison JA, Cottingham EM, Barton BA: Metformin for weight loss in pediatric patients taking psychotropic drugs. Am JPsychiatry 159:655-657, 2002.
12. Paolisso G, Amato L, Eccellente R, Gambardella A, Tagliamonte MR, Varricchio G, Carella C, Giugliano D, D'Onofrio F: Effect of metformin on food intake in obese subjects. Eur J Clin Invest28:441-446, 1998.
13. Srinivasan S, Ambler GR, Baur LA, Garnett SP, Tepsa M, Yap F, Ward GM, Cowell, CT: Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: Improvement in body composition and fastinginsulin. J Clin Endocrinol Metab 91:2074-2080, 2006.
14. Ventura J, Nuechterlein KH, Subotnik KL, Gutkind D, Gilbert EA: Symptom dimensions in recent-onset schizophrenia and mania: A principal components analysis of the 24-item BriefPsychiatric Rating Scale. Psychiatry Res 97: 129-135, 2000.
15. Washington State Department of Social and Health Services. Monitoring Of Side Effects Scale (MOSES). 2003. www.dshs.wa.gov/pdf/ms/forms/10-334.pdf. Last accessed May 25, 2009.
16. Webb E, Viner R: Should metformin be prescribed to overweight adolescents in whom dietary/behavioural modifications havenot helped? Arch Dis Child 91:793-794, 2006.
17. Wu R, Zhao J, Jin H, Shao P, Fang M, Guo X: Life-style intervention and metformin for treatment of antipsychotic-induced weight gain. JAMA 299:185-193, 2008a.
18. Wu RR, Zhao JP, Guo XF, He YQ, Fang MS, Guo WB, Chen JD, Li LH: Metformin addition attenuates olanzapine-induced weight gain in drug-naive first-episode schizophrenia patients: A double-blind, placebo-controlled study. Am J Psychiatry 165:352-358, 2008b.